IOMEPROL:
| Active name: | IOMEPROL |
| Brand name: | IOMERVU |
| Innovator name | BRACCO DIAGNOSTICS INC |
| Approval Date: | NOV 27, 2024 |
| Therapeutic activity: | Tri-iodinated X-Ray contrasting agent. Iomeprol has been investigated for the diagnostic of Coronary Artery Disease. |
| Route of administration | Intra arterial/intravenous, Injection |
| Structure | |
| Chemical name | N,N’-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)- methylamino]-2,4,6-tri-iodo-1,3-benzenedicarboxamide. |
| CAS | 78649-41-9 |
| Dosage | Available in four iodine concentration. 510 mg (250 mg rebound iodine), 612 mg (300 mg rebound iodine); 714 mg (350 mg rebound iodine); 816 mg (400 mg rebound iodine); |
| Molecular weight& molecular formuale | 777.09 g/mol & C17H22I3N3O8 (Iodine content 49%) |
| Solubility | water |
| NCE | 11/27/2029 |
| Solubility data | Soluble in water. |
| Hygroscopicity | Not hygroscopic |
| Drugbank | DB11705 |
| Chemspider | 3600 |
| Pubchem CID | 3731 |
Synthesis of Iomeprol:
ROS-1: Ref: EP 0026281A1
Iomeprol started with commercially available 5-amino-2,4,6-triiodoisophthalic acid, which was couple with formamide followed by thionoyl chloride to get the corresponding acid chloride. Coupling of acid chloride with 3-amino-1,2-propylene glycol to achieve the Iomeprol.
1H-NMR (DMSO-D 6)δ（ppm）：2.91(s, 4H)，3.21-3.36（m, 4H), 3.41-3.65（m, 4H), 3.85（s, 2H), 3.98（m,2H), 4.1-4.5（m,5H）, 8.2-8.4（d, 2H）； 13C-NMR（D 2O）δ（ppm）33.2，44.7，60.7，64.6，71.2，90.1，99.8，99.9，145.5，150.5，150.6，171.3，171.4，173.9.
ROS-2: CN 102363600B
Iomeprol started with commercially available 5-amino-2,4,6-triiodoisophthalic acid, which was couple with thionoyl chloride followed bychloro acetyl chloride to get the corresponding acid chloride. Coupling of acid chloride with 3-amino-1,2-propylene glycol, followed by treated with the sodium acetate to achieve the Iomeprol.
